



*Applicants*  
UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/930,781	8/15/01	Wu et al.	065125.0108

EXAMINER	
Anne-Marie Falk, Ph.D.	
ART UNIT	PAPER NUMBER
1632	11

Please find below a communication from the EXAMINER in charge of this application

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

**Sequences are disclosed in the specification that are not identified by their sequence identifier (i.e., SEQ ID NO:).** For example, at page 63, several primer sequences are disclosed, but none are identified by their sequence identifier. Applicants submitted a Sequence Listing on June 16, 2003, but the two sequences on page 63 are not included in the Sequence Listing.

**Applicant is reminded that the entire specification and figures should be reviewed for sequence disclosures** and that each sequence disclosed in the specification must be identified by its sequence identifier (i.e., SEQ ID NO:). The specification must be amended to identify all disclosed sequences by their sequence identifier (i.e., SEQ ID NO), in accordance with 37 CFR 1.821(d).

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Anne-Marie Falk, Ph.D. whose telephone number is (703) 306-9155. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner Deborah Reynolds whose telephone number is (703) 305-4051. The fax number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

SEP 2 1 2003

Application No. 09/930,781

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: The specification discloses sequences that are not included in the sequence listing. See e.g. page 63. The specification and/or figures must be amended to identify all disclosed sequences by their sequence identifier (i.e., SEQ ID NO), in accordance with 37 CFR 1.821(d). A substitute CRF and paper copy of the Sequence Listing are required.

**Applicant Must Provide:**

- ☒ A substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ A substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio  
(<http://www.uspto.gov/ebs/efs/downloads/documents.htm>), EFS  
Submission User Manual - ePAVE)

2. Mailed to:  
U.S. Patent and Trademark Office  
Mail Stop Sequence  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

3. Mailed by Federal Express, United Parcel Service or other delivery service to:  
U. S. Patent and Trademark Office  
2011 South Clark Place  
Customer Window, Mail Stop Sequence  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington, Virginia 22202

4. Hand Carried directly to the Customer Window at:  
2011 South Clark Place  
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,  
Arlington, Virginia 22202



# SEQUENCE LISTING

<110> Wu, George Y.  
Wu, Catherine H.

<120> PROPAGATION OF HUMAN HEPATOCYTES IN  
NON-HUMAN ANIMALS

<130> A34207-PCT-USA-A 065125.0108

<140> US 09/930,781

<141> 2001-08-15

<150> PCT/US00/05713

<151> 2000-03-03

<150> US 09/431,901

<151> 1999-11-02

<160> 13

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide probe

<400> 1

tgtgcttatg tagccatcca gcgagtcgcc

30

<210> 2

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 2

tcgcgaccca acactactc

19

<210> 3

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 3

gggggcgaca ctccacca

18

<210> 4

<211> 24

<212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Oligonucleotide primer  
 <400> 4  
 ccttggtggt gattgccttt gctc 24  
 <210> 5  
 <211> 24  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Oligonucleotide primer  
 <400> 5  
 catcacatca acctctgtct gacc 24  
 <210> 6  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Oligonucleotide primer  
 <400> 6  
 atagtgtccc agaaagctgg taggg 25  
 <210> 7  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Oligonucleotide primer  
 <400> 7  
 cggtttaagg acttaggaga acagc 25  
 <210> 8  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Oligonucleotide primer  
 <400> 8  
 atcttctgcg acgcggcgat ggagatc 27  
 <210> 9  
 <211> 29  
 <212> DNA  
 <213> Artificial Sequence  
 <220>

<223> Oligonucleotide primer

<400> 9

ctctgctggg gggaattgat gactctagc

29

<210> 10

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 10

gccggtctgg agcaaagctc atcgg

25

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 11

ggcgggtgtct aggagatctc tgac

24

<210> 12

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 12

ctggtctcac caatcggg

18

<210> 13

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide primer

<400> 13

ctggtctcac caatcggggg

20